These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17298198)

  • 21. An update on the use of antifungal agents.
    Martinez R
    J Bras Pneumol; 2006; 32(5):449-60. PubMed ID: 17268750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse reactions to voriconazole.
    Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW
    Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of cross-hepatotoxicity between voriconazole and posaconazole.
    Foo H; Gottlieb T
    Clin Infect Dis; 2007 Sep; 45(6):803-5. PubMed ID: 17712772
    [No Abstract]   [Full Text] [Related]  

  • 24. The safety of voriconazole.
    Potoski BA; Brown J
    Clin Infect Dis; 2002 Nov; 35(10):1273-5. PubMed ID: 12410490
    [No Abstract]   [Full Text] [Related]  

  • 25. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis.
    Jain LR; Denning DW
    J Infect; 2006 May; 52(5):e133-7. PubMed ID: 16427702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe acute hypokalaemia secondary to voriconazole. Uncommon pharmacological causes of hypokalaemia.
    González Rozas M; Alvarez Tundidor S; Pineda Alonso M
    Nefrologia; 2011; 31(1):112-3. PubMed ID: 21270925
    [No Abstract]   [Full Text] [Related]  

  • 27. Voriconazole therapy in children with cystic fibrosis.
    Hilliard T; Edwards S; Buchdahl R; Francis J; Rosenthal M; Balfour-Lynn I; Bush A; Davies J
    J Cyst Fibros; 2005 Dec; 4(4):215-20. PubMed ID: 16243008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amphotericin B is still the drug of choice for invasive aspergillosis.
    Agarwal R; Singh N
    Am J Respir Crit Care Med; 2006 Jul; 174(1):102; author reply 102-3. PubMed ID: 16793999
    [No Abstract]   [Full Text] [Related]  

  • 29. Secondary prophylaxis with voriconazole in a leukemic patient with pulmonary aspergillosis.
    Uriz J; de Andoin NG; Calvo C; Landa J; Onate E; Nogues A; Guerrero R
    Pediatr Infect Dis J; 2007 Oct; 26(10):971-2. PubMed ID: 17901816
    [No Abstract]   [Full Text] [Related]  

  • 30. Voriconazole. UK 109496.
    Drugs R D; 1999 Feb; 1(2):187-8. PubMed ID: 10566023
    [No Abstract]   [Full Text] [Related]  

  • 31. [Painful peripheral neuropathy associated with voriconazole during the treatment of chronic cavitary pulmonary aspergillosis].
    Gendrot A; de La Blanchardière A; de La Gastine B; Fromager G; Massias L; Verdon R
    Rev Med Interne; 2010 Feb; 31(2):163-6. PubMed ID: 19457596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
    Chandrasekar PH; Cutright J; Manavathu E
    J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Voriconazole in newborns.
    Kohli V; Taneja V; Sachdev P; Joshi R
    Indian Pediatr; 2008 Mar; 45(3):236-8. PubMed ID: 18367773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multifocal nodular periostitis associated with prolonged voriconazole therapy in a lung transplant recipient.
    Ayub A; Kenney CV; McKiernan FE
    J Clin Rheumatol; 2011 Mar; 17(2):73-5. PubMed ID: 21169844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Voriconazole - applications and perspectives].
    Ruhnke M
    Mycoses; 2002; 45 Suppl 3():42-7. PubMed ID: 12690971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of efficacy of voriconazole therapy in 2 patients with pulmonary fungus balls.
    Gutierrez F; Masia M; Ramos JM; Elia M; Rodriguez-Tudela JL; Cuenca-Estrella M
    Clin Infect Dis; 2005 Jun; 40(11):1706-7. PubMed ID: 15889381
    [No Abstract]   [Full Text] [Related]  

  • 37. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
    Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
    Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Voriconazole treatment for less-common, emerging, or refractory fungal infections.
    Perfect JR; Marr KA; Walsh TJ; Greenberg RN; DuPont B; de la Torre-Cisneros J; Just-Nübling G; Schlamm HT; Lutsar I; Espinel-Ingroff A; Johnson E
    Clin Infect Dis; 2003 May; 36(9):1122-31. PubMed ID: 12715306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse drug events complicate antifungal therapy for pulmonary aspergilloma.
    Pakyz A; Bearman G
    Consult Pharm; 2008 Oct; 23(10):804-8. PubMed ID: 19032016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease.
    van 't Hek LG; Verweij PE; Weemaes CM; van Dalen R; Yntema JB; Meis JF
    Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1694-6. PubMed ID: 9603157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.